Researchers at Germany’s Goethe University Frankfurt and the University of Michigan have created an enzyme capable of producing fluorinated antibiotics, which could make the vital drugs more accessible to the body and effective against pathogens that have developed resistance.
Active drug agents have been chemically modified with fluorine for decades, owing to fluorine’s ability to strengthen the bonding of the active agent to the target molecule, making it more accessible to the body as well as altering the time it spends in the body. Nearly half of the small-molecule drugs currently approved by the U.S. Food and Drug Administration contain at least one chemically bound fluorine atom.
Bacteria and fungi often manufacture complex natural compounds to obtain a growth advantage. One possible route for the development of drugs from natural compounds is to modify these substances by adding one or more fluorine atoms. However, the synthetic-chemical methods for inserting fluorine into natural substances are very complicated. Martin Grininger, coauthor and Professor for Organic Chemistry and Chemical Biology at Goethe University, says that, owing to the chemical and reaction conditions that are necessary, these methods are also frequently “brutal,” and “we are very limited in selecting the positions where the fluorine atom can be attached.”
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
In a recent issue of Nature Chemistry, the team, led by Grininger and David Sherman, Professor of Chemistry at the University of Michigan, details how they biosynthesized an antibiotic-producing bacteria. In this process, the fluorine atom is incorporated as part of a small substrate during the biological synthesis of a macrolide antibiotic. “We introduce the fluorinated unit during the natural manufacturing process, an approach that is both effective and elegant," says Grininger. "This gives us great flexibility when positioning the fluorine in the natural substance—and allows us to influence its efficacy."
Project leaders Dr. Alexander Rittner and Dr. Mirko Joppe, both members of Grininger’s research group in Frankfurt, inserted a subunit of an enzyme called fatty acid synthase into the bacterial protein. The enzyme is naturally involved in the biosynthesis of fats and fatty acids in mice. The fatty acid synthase is not very selective in processing the precursors, which are also important for the manufacture of antibiotics in bacteria, Rittner says. With an intelligent product design, the team succeeded in integrating a subunit of the murine enzyme into the corresponding biosynthetic process for the antibiotic.
"The exciting part is that, with erythromycin, we were able to fluorinate a representative of a gigantic substance class, the so-called polyketides," says Rittner. “There are about 10,000 known polyketides, many of which are used as natural medicines—for example, as antibiotics, immunosuppressives or cancer drugs. Our new method thus possesses a huge potential for the chemical optimization of this group of natural substances—in the antibiotics primarily to overcome antibiotic resistance."